• Home
  • >
  • Zydus Lifesciences Ltd Financials
https://storage.googleapis.com/assets.cdp.blinkx.in/BlinkxSearch/initials/z.svg Logo

Zydus Lifesciences Ltd Financial Statement

Zydus Lifesciences Ltd Income Statement
Quarterly
Annual

*All values are in Rs. Cr

(Rs. CR)Mar 2024Dec 2023Sep 2023
Revenue3,693.52,478.12,693.8
Operating Expense1,771.81,672.21,509.9
Net Profit1,405.2450.4805
Net Profit Margin38.0518.1829.88
Earning Per Share13.894.457.96
EBIDTA2,049.5800.81,192.4
Effective Tax Rate21.2114.7414.49

(Rs. Cr)

Revenue

Operating Expense

Net Profit

Net Profit Margin

Earning Per Share

EBIDTA

Effective Tax Rate

Zydus Lifesciences Ltd Profit & Loss

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Total Revenue Annual17,237.415,109.914,403.5
Operating Expenses Annual13,377.511,769.211,016.4
Operating Profit Annual3,437.75,923.83,159.6
Interest Annual129.9127158.8
Depreciation615.6595.1566.4
Net Profit Annual1,964.92,241.62,201.6
Tax Annual587.8511.7193.6

Particulars

Total Revenue Annual

Operating Expenses Annual

Operating Profit Annual

Interest Annual

Depreciation

Net Profit Annual

Tax Annual

Zydus Lifesciences Ltd Cash Flow

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Cash Flow at the Beginning1,106.9888.31,177.7
Cash Flow from Operations2,688.82,104.53,293.9
Cash Flow from Investing1,177.8-1,017.6-836.7
Cash Flow from Financing-4,400.4-868.3-2,547.7
Cash Flow at the End573.11,106.91,087.2

Particulars

Cash Flow at the Beginning

Cash Flow from Operations

Cash Flow from Investing

Cash Flow from Financing

Cash Flow at the End

Zydus Lifesciences Ltd Key Ratios

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
PBDIT Margin (%)23.3523.6123.86
PBIT Margin (%)19.1618.8919.21
PBT Margin (%)18.8718.618.99
Net PROFIT Margin (%)17.5110.9518.97
Return On Networth / Equity (%)14.0529.8220.32
Return On Networth /Employed(%)16.2514.4315.12
Return On Assets (%)13.497.5513.66
Total Debt / Equity(X)0.280.250.32
Asset Turnover Ratio (%)0.770.690.72

Particulars

PBDIT Margin (%)

PBIT Margin (%)

PBT Margin (%)

Net PROFIT Margin (%)

Return On Networth / Equity (%)

Return On Networth / Employed(%)

Return On Assets (%)

Total Debt / Equity(X)

Asset Turnover Ratio (%)

Zydus Lifesciences Ltd Balance Sheet

*All values are in Rs. Cr

Consolidated
Standalone
ParticularsMar 2023Mar 2022Mar 2021
Fixed Assets Annual11,591.412,253.412,132.8
Total Current Assets Annual10,008.212,095.28,716
Non Current Assets Annual15,74015,53415,168.7
Total Shareholders Funds Annual17,515.816,999.612,992.3
Total Assets Annual25,756.427,795.423,884.7

Particulars

Fixed Assets Annual

Total Current Assets Annual

Non Current Assets Annual

Total Shareholders Funds Annual

Total Assets Annual

Zydus Lifesciences Ltd Earning Calls
Mar 2024
EPS beaten by -0.51 %

Open Demat Account

50years
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O

Dividend Pages

PE Ratio

Get Your FAQs Right

As of May 20, 2024, Zydus Lifesciences Ltd has a market capitalization of 1,01,151.67 Cr. Value Research classifies it as a Large-Cap company.

Yes, Zydus Lifesciences Ltd is debt-free with a debt-to-equity ratio of 0.04.

In FY 2023, Zydus Lifesciences Ltd recorded a total revenue of approximately 19,021.5 Cr marking a significant milestone in the company's financial performance.

Zydus Lifesciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.5% and 0.1% annually, respectively..

Zydus Lifesciences Ltd's current PE ratio is 26.21.

Zydus Lifesciences Ltd's ROCE averaged 17.9% from the FY ending March 2022 to 2024, with a median of 17.7%. It peaked at 22.7% in March 2024, reflecting strong capital efficiency over the period..

Zydus Lifesciences Ltd's latest EBIT is Rs. 4,913.1 Cr, surpassing the average EBIT of Rs. 4,279.63 Cr over the 5 years..